Pharming Group NV (OTCMKTS:PHGUF – Get Free Report)’s stock price gapped down before the market opened on Friday. The stock had previously closed at $1.1050, but opened at $0.9545. Pharming Group shares last traded at $0.9545, with a volume of 1,000 shares changing hands.
Pharming Group Stock Performance
The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.31 and a current ratio of 3.01. The stock has a 50 day moving average of $1.10 and a 200 day moving average of $1.27. The stock has a market capitalization of $640.54 million, a P/E ratio of 79.54 and a beta of 0.42.
Pharming Group Company Profile
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing medicines for rare diseases and other conditions with limited treatment options. The company was founded in 1988 and has built its business around therapies produced using recombinant technology.
Pharming’s principal product is Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially life-threatening swelling.
Featured Articles
- Five stocks we like better than Pharming Group
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
